GENEVA–( BUSINESS WIRE )–Alcon Inc. (“Alcon”) (SIX/NYSE: ALC) announced that it has commenced and priced a private offering of US$700 million aggregate principal amount of its 5. 375% senior notes due 2032 and US$600 million aggregate principal amount of its 5. 750% senior notes due 2052 (together, the “Notes”). The Information will be issued by Alcon Finance Corporation, Alcon’s indirect subsidiary, and will be fully and unconditionally guaranteed on a senior basis simply by Alcon.
The offering is expected to close upon December 6, 2022, subject to customary closing conditions.
Alcon intends to use the proceeds from the offering for general corporate purposes, including the repayment of all outstanding indebtedness under the particular bridge facility entered into in connection with its acquisition of Aerie Pharmaceuticals, Inc., and in order to repay all or part of the outstanding indebtedness under the term loan facility.
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate, ” “intend, ” “commitment, ” “look forward, ” “maintain, ” “plan, ” “goal, ” “seek, ” “believe, ” “project, ” “estimate, ” “expect, ” “strategy, ” “future, ” “likely, ” “may, ” “should, ” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Alcon’s current beliefs, expectations and assumptions regarding the long term of Alcon’s business, upcoming plans plus strategies, and other future problems. Because forward-looking statements relate to the future, they are subject matter to inherent uncertainties and risks that are difficult in order to predict. Some of these factors are usually discussed in Alcon’s filings with the United States Investments and Exchange Commission, including Alcon’s Annual Report on Form 20-F. Should one or more of these types of uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.
Alcon assumes no obligation to update forward-looking claims as a result associated with new information, future events or otherwise.
This pr release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor will there end up being any sales of investments mentioned in this press release in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offers from the Notes will be made only simply by means of a personal offering memorandum to qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and to non-U. S. persons outside of the United States under Regulation S under the Securities Act.
The particular Notes have not been registered under the Securities Take action or maybe the securities laws associated with any other jurisdiction and may not be offered or sold in the United States absent registration or even an applicable exemption from registration requirements.
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight plus improve people’s lives. Our Surgical and Vision Care products touch the particular lives of more than 260 million people inside over 140 countries each year living along with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our own more than 24, 000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care.